What is your preferred approach to a patient with myeloma who has refractory disease to Dara-VRd in the frontline setting?

Answer from: Medical Oncologist at Community Practice

Unless the patient is not actually receiving some or all of the Dara-RVd (lenalidomide compliance can be challenging), this functionally defines high risk disease. Most patients don't usually have disease stability for autologous transplant, or even if they are stable for a hot second, transplant pr...

Comments

Medical Oncologist at University of Chicago
It’s a devastating situation! If cytopenias...

Medical Oncologist at Winship Cancer Institute of Emory University
The addition of cyclophosphamide in myeloma is gen...

Answer from: Medical Oncologist at Academic Institution

Agreed with @Craig C. Hofmeister's and @Ben Derman's excellent comments. I'd favor KPd as my general option here. And I agree wholeheartedly re: oral Cytoxan not being so useful and hyperCVAD/DCEP being very intense.UPDATE, SEPTEMBER 2024: The remainder of this response below presumes that second-li...

Please select the option that best describes you:

What is your preferred approach to a patient with myeloma who has refractory disease to Dara-VRd in the frontline setting?

Related Questions